MerTK signaling in human primary T cells modulates memory potential and improves recall response

Area of Science:

• Immunology
• Cancer Biology
• T cell Biology

Background:

• Cancer immunotherapies like checkpoint inhibitors and adoptive cell transfer have transformed treatment but benefit only a subset of patients.
• Understanding immune modulatory mechanisms is key to optimizing patient selection and enhancing anti-cancer immune responses.
• The TAM receptor MerTK signaling has been identified with a costimulatory role on activated human primary CD8+ T cells.

Purpose of the Study:

• To further investigate the costimulatory role of MerTK expression in human CD8+ T cells.
• To explore the characteristics and functional implications of MerTK expression on T cells.
• To assess the potential of targeting MerTK for improving cancer immunotherapy.

Main Methods:

• Analysis of MerTK expression on human primary CD8+ T cells.
• Characterization of MerTK-expressing cells using markers for T cell differentiation (CCR7, CD45RO, CD28, CD62L) and metabolic profiling.
• Assessment of proliferative capacity and cytokine production (IFNγ) upon recall responses in vitro.
• Evaluation of cytotoxicity and tumor-killing using gp100TCR-transduced T cells and PROS1 treatment.

Main Results:

• MerTK expression is linked to less differentiated Central Memory T cells, indicated by increased CCR7, CD45RO, CD28, and CD62L expression.
• MerTK-expressing T cells exhibit an altered metabolic profile.
• These cells demonstrate improved proliferative capacity and elevated IFNγ production in vitro recall responses.
• PROS1 treatment of T cells enhanced cytotoxicity and tumor-killing capacity.

Conclusions:

• MerTK expression plays a significant role in human CD8+ T cell function, particularly in less differentiated memory populations.
• MerTK-expressing T cells possess enhanced proliferative and effector functions, including improved IFNγ production.
• Targeting MerTK signaling, for example with PROS1, can augment T cell-mediated cytotoxicity against tumors.
• These findings suggest MerTK as a potential target for improving the efficacy of cancer immunotherapies.